| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Diseases | 10 | 2023 | 485 | 2.140 |
Why?
|
| Urethral Obstruction | 8 | 2023 | 56 | 1.420 |
Why?
|
| Kidney | 18 | 2023 | 1363 | 1.200 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 4 | 2011 | 16 | 1.040 |
Why?
|
| Nephrosis, Lipoid | 2 | 2023 | 11 | 1.010 |
Why?
|
| Glomerulonephritis | 6 | 2019 | 74 | 1.000 |
Why?
|
| Fetal Diseases | 9 | 2023 | 456 | 1.000 |
Why?
|
| Hypertension | 12 | 2023 | 1332 | 0.970 |
Why?
|
| Nephrotic Syndrome | 2 | 2023 | 52 | 0.960 |
Why?
|
| Nephrology | 2 | 2024 | 148 | 0.920 |
Why?
|
| Kidney Failure, Chronic | 6 | 2023 | 887 | 0.910 |
Why?
|
| Urinary Bladder Neck Obstruction | 4 | 2018 | 29 | 0.910 |
Why?
|
| Interleukin-12 | 6 | 2009 | 116 | 0.780 |
Why?
|
| Receptors, Complement | 4 | 2009 | 32 | 0.730 |
Why?
|
| Kidney Transplantation | 4 | 2011 | 652 | 0.690 |
Why?
|
| Urinary Tract | 3 | 2020 | 60 | 0.680 |
Why?
|
| Renal Insufficiency | 3 | 2017 | 239 | 0.620 |
Why?
|
| Receptors, Immunologic | 2 | 2014 | 113 | 0.620 |
Why?
|
| Hypertension, Renal | 3 | 2018 | 38 | 0.610 |
Why?
|
| Lupus Nephritis | 2 | 2009 | 42 | 0.590 |
Why?
|
| Denys-Drash Syndrome | 1 | 2017 | 5 | 0.570 |
Why?
|
| WT1 Proteins | 1 | 2017 | 27 | 0.560 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 2017 | 36 | 0.550 |
Why?
|
| Rats, Inbred SHR | 11 | 2023 | 65 | 0.540 |
Why?
|
| Urogenital Abnormalities | 2 | 2016 | 152 | 0.540 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2021 | 736 | 0.540 |
Why?
|
| Chromosome Mapping | 5 | 2018 | 1086 | 0.530 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2020 | 3175 | 0.530 |
Why?
|
| Mice, Inbred MRL lpr | 4 | 2009 | 16 | 0.520 |
Why?
|
| Proteome | 2 | 2009 | 246 | 0.510 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2015 | 36 | 0.480 |
Why?
|
| Stroke | 6 | 2023 | 976 | 0.460 |
Why?
|
| Proteomics | 2 | 2009 | 506 | 0.450 |
Why?
|
| Graft Survival | 3 | 2011 | 531 | 0.430 |
Why?
|
| Genetic Variation | 4 | 2023 | 1505 | 0.420 |
Why?
|
| Nephritis, Hereditary | 2 | 2022 | 21 | 0.400 |
Why?
|
| Receptor, Anaphylatoxin C5a | 4 | 2007 | 12 | 0.370 |
Why?
|
| Renal Replacement Therapy | 3 | 2018 | 146 | 0.370 |
Why?
|
| Monocytes | 4 | 2001 | 345 | 0.360 |
Why?
|
| Humans | 63 | 2024 | 125309 | 0.360 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2020 | 471 | 0.350 |
Why?
|
| Dendritic Cells | 6 | 2009 | 414 | 0.340 |
Why?
|
| Retrospective Studies | 20 | 2023 | 16360 | 0.330 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 1 | 2009 | 8 | 0.330 |
Why?
|
| Hemodiafiltration | 2 | 2021 | 18 | 0.330 |
Why?
|
| Kidney Tubules | 2 | 2013 | 78 | 0.320 |
Why?
|
| Mutation | 4 | 2022 | 5903 | 0.310 |
Why?
|
| Female | 41 | 2023 | 66791 | 0.310 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2008 | 5 | 0.310 |
Why?
|
| Kidney Glomerulus | 4 | 2013 | 77 | 0.310 |
Why?
|
| Ultrasonography, Prenatal | 7 | 2023 | 972 | 0.310 |
Why?
|
| Proteinuria | 2 | 2006 | 105 | 0.300 |
Why?
|
| Complement C3a | 2 | 2007 | 19 | 0.300 |
Why?
|
| Albuminuria | 3 | 2014 | 103 | 0.300 |
Why?
|
| Renal Dialysis | 4 | 2023 | 862 | 0.300 |
Why?
|
| Sulfhydryl Compounds | 1 | 2008 | 54 | 0.300 |
Why?
|
| Urinary Bladder | 4 | 2023 | 244 | 0.300 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2008 | 63 | 0.300 |
Why?
|
| Fetus | 3 | 2023 | 586 | 0.300 |
Why?
|
| Signal Transduction | 3 | 2014 | 4595 | 0.290 |
Why?
|
| Urologic Diseases | 2 | 2019 | 44 | 0.290 |
Why?
|
| Animals | 26 | 2023 | 34309 | 0.280 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2020 | 2652 | 0.280 |
Why?
|
| Haplotypes | 5 | 2019 | 521 | 0.280 |
Why?
|
| Glomerular Filtration Rate | 3 | 2021 | 510 | 0.280 |
Why?
|
| Complement Factor H | 2 | 2008 | 21 | 0.280 |
Why?
|
| Prenatal Care | 2 | 2023 | 348 | 0.270 |
Why?
|
| Plasma Exchange | 2 | 2018 | 84 | 0.270 |
Why?
|
| Graft Rejection | 1 | 2011 | 586 | 0.270 |
Why?
|
| Complement C4 | 1 | 2007 | 5 | 0.270 |
Why?
|
| Rats | 8 | 2023 | 3726 | 0.270 |
Why?
|
| Histocompatibility Antigens | 1 | 2007 | 19 | 0.270 |
Why?
|
| Child | 22 | 2024 | 24608 | 0.270 |
Why?
|
| Immunosuppressive Agents | 3 | 2014 | 645 | 0.270 |
Why?
|
| Kidney Tubules, Proximal | 2 | 2004 | 107 | 0.260 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 2019 | 49 | 0.250 |
Why?
|
| Infant | 16 | 2023 | 12602 | 0.250 |
Why?
|
| Genome-Wide Association Study | 2 | 2014 | 1694 | 0.250 |
Why?
|
| Mycophenolic Acid | 2 | 2016 | 49 | 0.250 |
Why?
|
| Glomerulonephritis, IGA | 2 | 2018 | 16 | 0.250 |
Why?
|
| Cholera Toxin | 2 | 2009 | 49 | 0.240 |
Why?
|
| Animals, Congenic | 3 | 2020 | 6 | 0.230 |
Why?
|
| Cytomegalovirus Infections | 1 | 2007 | 223 | 0.230 |
Why?
|
| Male | 29 | 2022 | 61531 | 0.230 |
Why?
|
| Pregnancy | 10 | 2023 | 7225 | 0.230 |
Why?
|
| Protein Methyltransferases | 1 | 2004 | 9 | 0.220 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2007 | 193 | 0.220 |
Why?
|
| Prognosis | 7 | 2018 | 4685 | 0.220 |
Why?
|
| Blood Pressure | 5 | 2023 | 1377 | 0.220 |
Why?
|
| Glomerular Mesangium | 3 | 2003 | 19 | 0.220 |
Why?
|
| Time Factors | 7 | 2017 | 6308 | 0.210 |
Why?
|
| Reperfusion Injury | 1 | 2004 | 114 | 0.210 |
Why?
|
| Glomerulonephritis, Membranous | 2 | 2018 | 12 | 0.200 |
Why?
|
| Gene Expression Profiling | 3 | 2008 | 1756 | 0.200 |
Why?
|
| Creatinine | 2 | 2021 | 394 | 0.200 |
Why?
|
| Risk Factors | 8 | 2021 | 10296 | 0.200 |
Why?
|
| Disease Progression | 5 | 2018 | 2083 | 0.200 |
Why?
|
| Steroids | 1 | 2023 | 202 | 0.200 |
Why?
|
| Mice | 13 | 2012 | 17743 | 0.200 |
Why?
|
| Cystoscopy | 3 | 2017 | 44 | 0.190 |
Why?
|
| Transplantation, Homologous | 3 | 2011 | 621 | 0.190 |
Why?
|
| Hematuria | 1 | 2022 | 54 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2016 | 1065 | 0.190 |
Why?
|
| Biomarkers | 2 | 2018 | 3102 | 0.190 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2001 | 7 | 0.180 |
Why?
|
| Ultrasonography | 2 | 2023 | 939 | 0.180 |
Why?
|
| Receptors, Peptide | 1 | 2001 | 50 | 0.180 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2001 | 28 | 0.180 |
Why?
|
| Cells, Cultured | 7 | 2020 | 3043 | 0.180 |
Why?
|
| Consensus | 1 | 2024 | 644 | 0.180 |
Why?
|
| Child, Preschool | 13 | 2021 | 14145 | 0.170 |
Why?
|
| Stromal Interaction Molecule 1 | 1 | 2020 | 7 | 0.170 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2000 | 8 | 0.170 |
Why?
|
| ORAI1 Protein | 1 | 2020 | 4 | 0.170 |
Why?
|
| Crosses, Genetic | 2 | 2013 | 163 | 0.170 |
Why?
|
| Autoantibodies | 2 | 2020 | 432 | 0.170 |
Why?
|
| Antigens, CD | 2 | 2000 | 430 | 0.170 |
Why?
|
| Lymphocytes | 2 | 2014 | 408 | 0.170 |
Why?
|
| Mice, Knockout | 5 | 2012 | 3753 | 0.170 |
Why?
|
| Mice, Inbred C57BL | 5 | 2012 | 4420 | 0.170 |
Why?
|
| Perinatal Mortality | 2 | 2019 | 43 | 0.160 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2019 | 39 | 0.160 |
Why?
|
| Disease Models, Animal | 7 | 2020 | 4406 | 0.160 |
Why?
|
| Foreign-Body Migration | 2 | 2018 | 71 | 0.160 |
Why?
|
| RNA, Messenger | 6 | 2004 | 2812 | 0.160 |
Why?
|
| Prednisone | 1 | 1999 | 278 | 0.160 |
Why?
|
| Receptors, Interleukin | 1 | 1999 | 33 | 0.160 |
Why?
|
| Complement C5a | 3 | 2007 | 24 | 0.150 |
Why?
|
| Receptors, Cell Surface | 1 | 2001 | 477 | 0.150 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2018 | 32 | 0.150 |
Why?
|
| Quantitative Trait Loci | 3 | 2018 | 287 | 0.150 |
Why?
|
| Nervous System Malformations | 1 | 2020 | 130 | 0.150 |
Why?
|
| Germ Cells | 1 | 2019 | 196 | 0.150 |
Why?
|
| Hypertension, Renovascular | 1 | 2018 | 29 | 0.150 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2019 | 246 | 0.150 |
Why?
|
| Complement C3 | 2 | 2013 | 48 | 0.150 |
Why?
|
| Recurrence | 3 | 2011 | 1394 | 0.150 |
Why?
|
| Infant, Newborn | 8 | 2020 | 8273 | 0.150 |
Why?
|
| Extracorporeal Circulation | 1 | 2018 | 55 | 0.150 |
Why?
|
| Receptors, Fc | 1 | 2018 | 29 | 0.150 |
Why?
|
| Urologic Surgical Procedures | 1 | 2018 | 57 | 0.150 |
Why?
|
| Chromosomes, Mammalian | 1 | 2018 | 41 | 0.140 |
Why?
|
| Nephritis | 1 | 2018 | 20 | 0.140 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2018 | 30 | 0.140 |
Why?
|
| Edema | 1 | 2019 | 137 | 0.140 |
Why?
|
| Renal Artery Obstruction | 1 | 2018 | 39 | 0.140 |
Why?
|
| Mitochondrial Diseases | 1 | 2019 | 132 | 0.140 |
Why?
|
| Ammonia | 1 | 1998 | 76 | 0.140 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 700 | 0.140 |
Why?
|
| Survival Analysis | 4 | 2018 | 1494 | 0.140 |
Why?
|
| Anesthesia, General | 1 | 2018 | 118 | 0.140 |
Why?
|
| Catheters, Indwelling | 1 | 2018 | 153 | 0.140 |
Why?
|
| Citric Acid | 1 | 2017 | 37 | 0.140 |
Why?
|
| Peptide Fragments | 1 | 2001 | 781 | 0.140 |
Why?
|
| Lung | 3 | 2015 | 1487 | 0.140 |
Why?
|
| Immunohistochemistry | 4 | 2018 | 1703 | 0.140 |
Why?
|
| Glucocorticoids | 1 | 1999 | 384 | 0.130 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2018 | 72 | 0.130 |
Why?
|
| Membrane Proteins | 1 | 2004 | 1538 | 0.130 |
Why?
|
| Peritoneal Dialysis | 1 | 2018 | 127 | 0.130 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 1901 | 0.130 |
Why?
|
| Hematocrit | 2 | 2014 | 114 | 0.130 |
Why?
|
| Forecasting | 1 | 2018 | 352 | 0.130 |
Why?
|
| Fetal Therapies | 1 | 2017 | 80 | 0.130 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 1996 | 15 | 0.130 |
Why?
|
| Liver Failure, Acute | 1 | 2017 | 89 | 0.130 |
Why?
|
| Coatomer Protein | 1 | 2016 | 30 | 0.130 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2016 | 81 | 0.120 |
Why?
|
| Adolescent | 11 | 2020 | 19424 | 0.120 |
Why?
|
| Atypical Hemolytic Uremic Syndrome | 1 | 2015 | 9 | 0.120 |
Why?
|
| Biopsy | 3 | 2022 | 1244 | 0.120 |
Why?
|
| Prosthesis Failure | 1 | 2016 | 156 | 0.120 |
Why?
|
| Cell Cycle Proteins | 1 | 2019 | 664 | 0.120 |
Why?
|
| Interferon-gamma | 5 | 2012 | 505 | 0.120 |
Why?
|
| Lung Diseases | 2 | 2016 | 384 | 0.120 |
Why?
|
| Cytokines | 2 | 2000 | 1289 | 0.120 |
Why?
|
| Cyclic AMP | 2 | 2009 | 247 | 0.120 |
Why?
|
| Electrocoagulation | 1 | 2015 | 35 | 0.120 |
Why?
|
| Pediatrics | 1 | 2024 | 1158 | 0.120 |
Why?
|
| Urinary Fistula | 1 | 2015 | 20 | 0.120 |
Why?
|
| Adult | 11 | 2020 | 29528 | 0.120 |
Why?
|
| Urethra | 1 | 2015 | 85 | 0.120 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2014 | 2 | 0.120 |
Why?
|
| Drainage | 1 | 2016 | 260 | 0.110 |
Why?
|
| Polycystic Kidney, Autosomal Recessive | 1 | 2014 | 9 | 0.110 |
Why?
|
| Young Adult | 7 | 2020 | 9055 | 0.110 |
Why?
|
| Risk Assessment | 5 | 2019 | 3431 | 0.110 |
Why?
|
| Hospital Mortality | 2 | 2017 | 1027 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 649 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 205 | 0.110 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 375 | 0.110 |
Why?
|
| Gestational Age | 4 | 2020 | 1169 | 0.110 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 2519 | 0.110 |
Why?
|
| Immunoglobulin G | 2 | 2019 | 779 | 0.100 |
Why?
|
| Patient Selection | 1 | 2017 | 696 | 0.100 |
Why?
|
| Hemoglobins | 1 | 2014 | 312 | 0.100 |
Why?
|
| Alleles | 2 | 2014 | 1617 | 0.100 |
Why?
|
| Fetoscopy | 1 | 2017 | 447 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 2181 | 0.100 |
Why?
|
| Species Specificity | 3 | 2014 | 551 | 0.100 |
Why?
|
| Complement C7 | 1 | 2012 | 2 | 0.100 |
Why?
|
| Liver Transplantation | 2 | 2018 | 1042 | 0.100 |
Why?
|
| Anticoagulants | 1 | 2017 | 578 | 0.100 |
Why?
|
| Prenatal Diagnosis | 4 | 2018 | 600 | 0.100 |
Why?
|
| Laser Therapy | 1 | 2015 | 249 | 0.100 |
Why?
|
| Treatment Outcome | 7 | 2018 | 12282 | 0.100 |
Why?
|
| Survival Rate | 2 | 2008 | 2049 | 0.100 |
Why?
|
| Biopsy, Needle | 2 | 2018 | 228 | 0.090 |
Why?
|
| Molecular Sequence Data | 3 | 2014 | 3897 | 0.090 |
Why?
|
| CD40 Ligand | 2 | 2002 | 62 | 0.090 |
Why?
|
| Fibrosis | 1 | 2013 | 441 | 0.090 |
Why?
|
| Cognitive Dysfunction | 1 | 2015 | 233 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 509 | 0.090 |
Why?
|
| Middle Aged | 8 | 2019 | 26741 | 0.090 |
Why?
|
| Brain Injuries | 1 | 2016 | 702 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 963 | 0.090 |
Why?
|
| Epigenomics | 1 | 2012 | 176 | 0.090 |
Why?
|
| Databases as Topic | 1 | 2011 | 73 | 0.090 |
Why?
|
| Virulence Factors, Bordetella | 2 | 2001 | 23 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 1156 | 0.090 |
Why?
|
| Cognition | 1 | 2015 | 721 | 0.080 |
Why?
|
| Population Groups | 1 | 2010 | 30 | 0.080 |
Why?
|
| Stress, Psychological | 1 | 2015 | 550 | 0.080 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2012 | 217 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 586 | 0.080 |
Why?
|
| Endovascular Procedures | 1 | 2018 | 726 | 0.080 |
Why?
|
| Drug Administration Schedule | 3 | 2015 | 730 | 0.080 |
Why?
|
| Abnormalities, Multiple | 1 | 2015 | 960 | 0.080 |
Why?
|
| Hepcidins | 1 | 2009 | 26 | 0.080 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2009 | 38 | 0.080 |
Why?
|
| Quality of Life | 1 | 2019 | 1909 | 0.080 |
Why?
|
| CD8 Antigens | 1 | 2009 | 41 | 0.080 |
Why?
|
| Interferon Regulatory Factors | 1 | 2009 | 37 | 0.080 |
Why?
|
| Immunoassay | 1 | 2009 | 131 | 0.080 |
Why?
|
| Calcium | 3 | 2020 | 1105 | 0.080 |
Why?
|
| Chemokine CCL2 | 2 | 2000 | 123 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 1 | 2010 | 239 | 0.080 |
Why?
|
| Hepatocyte Nuclear Factor 1 | 1 | 2008 | 3 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 1763 | 0.070 |
Why?
|
| Amniotic Fluid | 2 | 2020 | 150 | 0.070 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2012 | 383 | 0.070 |
Why?
|
| Macrophages | 1 | 2012 | 625 | 0.070 |
Why?
|
| Calcium Signaling | 2 | 2020 | 244 | 0.070 |
Why?
|
| Mass Spectrometry | 1 | 2009 | 335 | 0.070 |
Why?
|
| Mediastinitis | 1 | 2008 | 14 | 0.070 |
Why?
|
| Tissue and Organ Procurement | 1 | 2011 | 222 | 0.070 |
Why?
|
| Oligohydramnios | 2 | 2019 | 46 | 0.070 |
Why?
|
| Prospective Studies | 5 | 2021 | 6140 | 0.070 |
Why?
|
| Cryptococcosis | 1 | 2008 | 42 | 0.070 |
Why?
|
| Genotype | 1 | 2013 | 2569 | 0.070 |
Why?
|
| Gram-Negative Bacteria | 1 | 2007 | 68 | 0.070 |
Why?
|
| Gene Targeting | 1 | 2007 | 177 | 0.070 |
Why?
|
| United States | 4 | 2024 | 10907 | 0.070 |
Why?
|
| Base Sequence | 2 | 2014 | 3109 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 2908 | 0.060 |
Why?
|
| Shock, Septic | 1 | 2007 | 147 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2010 | 420 | 0.060 |
Why?
|
| Peptides | 1 | 2009 | 812 | 0.060 |
Why?
|
| Pedigree | 2 | 2022 | 1609 | 0.060 |
Why?
|
| Aged | 5 | 2019 | 19711 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2010 | 1187 | 0.060 |
Why?
|
| Linear Models | 2 | 2018 | 683 | 0.060 |
Why?
|
| Immunophenotyping | 1 | 2005 | 327 | 0.060 |
Why?
|
| Expressed Sequence Tags | 1 | 2004 | 79 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 818 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 6552 | 0.060 |
Why?
|
| North America | 1 | 2005 | 243 | 0.060 |
Why?
|
| Nephrologists | 1 | 2024 | 13 | 0.060 |
Why?
|
| Complement Activation | 1 | 2004 | 52 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 1427 | 0.060 |
Why?
|
| Prevalence | 1 | 2011 | 2466 | 0.060 |
Why?
|
| Reference Values | 1 | 2005 | 719 | 0.060 |
Why?
|
| Self Report | 2 | 2019 | 508 | 0.060 |
Why?
|
| Cell Division | 3 | 2003 | 780 | 0.050 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2004 | 43 | 0.050 |
Why?
|
| Apoptosis | 2 | 2008 | 1817 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1240 | 0.050 |
Why?
|
| Urothelium | 1 | 2004 | 60 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2014 | 2717 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2004 | 472 | 0.050 |
Why?
|
| Bacteremia | 1 | 2007 | 407 | 0.050 |
Why?
|
| Acute Disease | 3 | 2007 | 1096 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2005 | 691 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2012 | 680 | 0.050 |
Why?
|
| Homozygote | 2 | 2019 | 548 | 0.050 |
Why?
|
| Transcription, Genetic | 2 | 2008 | 1705 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1244 | 0.050 |
Why?
|
| Immune Sera | 1 | 2003 | 95 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2024 | 210 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2015 | 3055 | 0.050 |
Why?
|
| Leishmania tropica | 1 | 2002 | 1 | 0.050 |
Why?
|
| Interleukin-10 | 2 | 2002 | 174 | 0.050 |
Why?
|
| Leishmania major | 1 | 2002 | 27 | 0.050 |
Why?
|
| Collagen Type IV | 1 | 2022 | 20 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2023 | 266 | 0.050 |
Why?
|
| CD40 Antigens | 1 | 2002 | 25 | 0.050 |
Why?
|
| Leishmania donovani | 1 | 2002 | 23 | 0.050 |
Why?
|
| Epithelial Cells | 2 | 2004 | 909 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2005 | 415 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 1587 | 0.050 |
Why?
|
| Autoantigens | 1 | 2022 | 118 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2009 | 1908 | 0.050 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 2001 | 11 | 0.050 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2001 | 17 | 0.050 |
Why?
|
| Receptors, Formyl Peptide | 1 | 2001 | 5 | 0.050 |
Why?
|
| Pertussis Toxin | 1 | 2001 | 28 | 0.050 |
Why?
|
| Nephrectomy | 1 | 2022 | 178 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 1033 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2001 | 69 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2001 | 2524 | 0.040 |
Why?
|
| Interleukin-4 | 1 | 2001 | 140 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2001 | 118 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2008 | 1720 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 2057 | 0.040 |
Why?
|
| Chemokine CCL8 | 1 | 2000 | 1 | 0.040 |
Why?
|
| Chemokine CCL7 | 1 | 2000 | 7 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2024 | 700 | 0.040 |
Why?
|
| Rats, Transgenic | 1 | 2020 | 15 | 0.040 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2020 | 20 | 0.040 |
Why?
|
| Caribbean Region | 1 | 2019 | 19 | 0.040 |
Why?
|
| Phenotype | 2 | 2019 | 4269 | 0.040 |
Why?
|
| NFATC Transcription Factors | 1 | 2020 | 43 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 1275 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2014 | 725 | 0.040 |
Why?
|
| Sex Factors | 2 | 2018 | 1275 | 0.040 |
Why?
|
| Serum Albumin | 1 | 1999 | 113 | 0.040 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2019 | 70 | 0.040 |
Why?
|
| RNA Splice Sites | 1 | 2019 | 90 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2020 | 121 | 0.040 |
Why?
|
| Calcium Channels | 1 | 2020 | 160 | 0.040 |
Why?
|
| Receptors, Interleukin-12 | 1 | 1999 | 9 | 0.040 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2019 | 166 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2020 | 172 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2019 | 212 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 1999 | 89 | 0.040 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1998 | 43 | 0.040 |
Why?
|
| CD3 Complex | 1 | 1999 | 91 | 0.040 |
Why?
|
| Amino Acids | 1 | 2021 | 668 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 88 | 0.040 |
Why?
|
| Th2 Cells | 1 | 1999 | 185 | 0.040 |
Why?
|
| Rehabilitation | 1 | 2018 | 24 | 0.040 |
Why?
|
| Hemofiltration | 1 | 1998 | 11 | 0.040 |
Why?
|
| Th1 Cells | 1 | 1999 | 153 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1998 | 461 | 0.040 |
Why?
|
| Immune System Diseases | 1 | 2018 | 47 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 1999 | 297 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2020 | 761 | 0.030 |
Why?
|
| Exons | 1 | 2019 | 801 | 0.030 |
Why?
|
| Conservative Treatment | 1 | 2017 | 36 | 0.030 |
Why?
|
| beta 2-Microglobulin | 1 | 2016 | 34 | 0.030 |
Why?
|
| Age Factors | 2 | 2018 | 2817 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 1999 | 381 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 309 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 237 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 2017 | 163 | 0.030 |
Why?
|
| PAX2 Transcription Factor | 1 | 2016 | 27 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2018 | 130 | 0.030 |
Why?
|
| Critical Illness | 1 | 2021 | 600 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2016 | 30 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 2016 | 176 | 0.030 |
Why?
|
| Chlorides | 1 | 2016 | 107 | 0.030 |
Why?
|
| Brain Edema | 1 | 2016 | 68 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2016 | 79 | 0.030 |
Why?
|
| Antibodies | 1 | 2018 | 374 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 130 | 0.030 |
Why?
|
| Arthritis | 1 | 2016 | 81 | 0.030 |
Why?
|
| Sodium | 1 | 2016 | 299 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 1961 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2010 | 1361 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2016 | 286 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1320 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1999 | 1692 | 0.030 |
Why?
|
| France | 1 | 2015 | 80 | 0.030 |
Why?
|
| Brazil | 1 | 2015 | 123 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 880 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 5165 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 360 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2014 | 291 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2020 | 1016 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2009 | 1001 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 1520 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 560 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2014 | 658 | 0.030 |
Why?
|
| International Cooperation | 1 | 2013 | 157 | 0.030 |
Why?
|
| Disease Management | 1 | 2016 | 530 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 219 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2007 | 802 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2016 | 826 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 907 | 0.020 |
Why?
|
| Anemia | 1 | 2014 | 341 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 1284 | 0.020 |
Why?
|
| Germany | 1 | 2010 | 66 | 0.020 |
Why?
|
| Carboplatin | 1 | 2010 | 77 | 0.020 |
Why?
|
| Taxoids | 1 | 2010 | 67 | 0.020 |
Why?
|
| Microvessels | 1 | 2010 | 57 | 0.020 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2009 | 14 | 0.020 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2009 | 15 | 0.020 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2009 | 19 | 0.020 |
Why?
|
| Inflammation | 1 | 2016 | 1445 | 0.020 |
Why?
|
| Hospitalization | 1 | 2018 | 1791 | 0.020 |
Why?
|
| Toxoplasmosis | 1 | 2009 | 21 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 887 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 366 | 0.020 |
Why?
|
| Rats, Inbred WKY | 1 | 2008 | 54 | 0.020 |
Why?
|
| Spleen | 1 | 2009 | 281 | 0.020 |
Why?
|
| Cryptococcus neoformans | 1 | 2008 | 21 | 0.020 |
Why?
|
| Tomography, Spiral Computed | 1 | 2008 | 16 | 0.020 |
Why?
|
| Antigens, Fungal | 1 | 2008 | 34 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2010 | 206 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3307 | 0.020 |
Why?
|
| Animal Feed | 1 | 2008 | 77 | 0.020 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2015 | 623 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 344 | 0.020 |
Why?
|
| Histamine Antagonists | 1 | 2007 | 19 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2013 | 518 | 0.020 |
Why?
|
| Macrophages, Peritoneal | 1 | 2007 | 38 | 0.020 |
Why?
|
| Platelet Count | 1 | 2007 | 137 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2008 | 117 | 0.020 |
Why?
|
| Mast Cells | 1 | 2007 | 78 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 1269 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2008 | 442 | 0.020 |
Why?
|
| Carotid Artery Diseases | 1 | 2008 | 141 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2009 | 395 | 0.020 |
Why?
|
| Depression | 1 | 2015 | 1230 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 299 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3602 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 2008 | 264 | 0.020 |
Why?
|
| Family Practice | 1 | 2005 | 91 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2007 | 372 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 2005 | 112 | 0.010 |
Why?
|
| Coronary Disease | 1 | 2008 | 675 | 0.010 |
Why?
|
| Mice, Congenic | 1 | 2003 | 16 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2003 | 121 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2003 | 108 | 0.010 |
Why?
|
| Endotoxins | 1 | 2003 | 48 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2008 | 818 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 2003 | 118 | 0.010 |
Why?
|
| Life Style | 1 | 2005 | 415 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2003 | 204 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2003 | 309 | 0.010 |
Why?
|
| Sheep | 1 | 2003 | 220 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 2003 | 173 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2003 | 426 | 0.010 |
Why?
|
| Weight Loss | 1 | 2005 | 482 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2003 | 586 | 0.010 |
Why?
|
| Kidney Tubules, Distal | 1 | 2000 | 16 | 0.010 |
Why?
|
| U937 Cells | 1 | 2000 | 24 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2000 | 106 | 0.010 |
Why?
|
| Growth Substances | 1 | 2000 | 113 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2000 | 139 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 2000 | 136 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2002 | 465 | 0.010 |
Why?
|
| Exercise | 1 | 2005 | 814 | 0.010 |
Why?
|
| Ureter | 1 | 2000 | 94 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2000 | 824 | 0.010 |
Why?
|
| Diet | 1 | 2005 | 1138 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 2755 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2000 | 1293 | 0.010 |
Why?
|